CL2017001960A1 - Métodos de tratamiento de enfermedades inflamatorias - Google Patents

Métodos de tratamiento de enfermedades inflamatorias

Info

Publication number
CL2017001960A1
CL2017001960A1 CL2017001960A CL2017001960A CL2017001960A1 CL 2017001960 A1 CL2017001960 A1 CL 2017001960A1 CL 2017001960 A CL2017001960 A CL 2017001960A CL 2017001960 A CL2017001960 A CL 2017001960A CL 2017001960 A1 CL2017001960 A1 CL 2017001960A1
Authority
CL
Chile
Prior art keywords
methods
inflammatory diseases
treating inflammatory
spa
diseases
Prior art date
Application number
CL2017001960A
Other languages
English (en)
Inventor
Annette Bettina Galler
Steven John Padula
Amtthias Arndt
Stella Aslanyan
Mary Ruth Flack
Bojan LALOVIC
Paul Rusell Scholl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2017001960A1 publication Critical patent/CL2017001960A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE EN GENERAL A MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-23, EN PARTICULAR, ENFERMEDADES INFLAMATORIAS, TALES COMO PSORIASIS, ARTRITIS PSORIÁSICA O ESPONDTLOARTRITIS AXIAL (ESPINAL) (AX-SPA), QUE INCLUYE IA ESPONDILITIS ANQUILOSANTE Y LA AX-SPA NO RADIOGRÁFICA, QUE UTILIZAN ANTICUERPOS ANTI-LL-23A.</p>
CL2017001960A 2015-02-04 2017-08-01 Métodos de tratamiento de enfermedades inflamatorias CL2017001960A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US201562235631P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
CL2017001960A1 true CL2017001960A1 (es) 2018-04-20

Family

ID=55453266

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001960A CL2017001960A1 (es) 2015-02-04 2017-08-01 Métodos de tratamiento de enfermedades inflamatorias

Country Status (15)

Country Link
US (1) US20160222102A1 (es)
EP (1) EP3253794A1 (es)
JP (5) JP6758304B2 (es)
KR (1) KR20170120616A (es)
CN (2) CN107206081A (es)
AU (2) AU2016215535B2 (es)
BR (1) BR112017014684A2 (es)
CA (1) CA2972995A1 (es)
CL (1) CL2017001960A1 (es)
EA (1) EA201791734A1 (es)
IL (2) IL307578A (es)
MX (3) MX2017010037A (es)
PH (1) PH12017501378A1 (es)
SG (2) SG11201705728RA (es)
WO (1) WO2016126638A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201706733B (en) 2010-11-04 2017-09-25 Boehringer Ingelheim Int Anti-il-23 antibodies
EP3326649B1 (en) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
US20160222102A1 (en) * 2015-02-04 2016-08-04 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3974451A3 (en) * 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
KR20190059305A (ko) * 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
CN106778030B (zh) * 2017-01-10 2023-04-07 广州和康医疗技术有限公司 一种强直性脊柱炎病情监测管理系统及其监测管理方法
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
US20210070852A1 (en) * 2019-09-09 2021-03-11 Boehringer Ingelheim International Gmbh Anti-IL-23p19 Antibody Formulations
US20230303678A1 (en) * 2022-01-25 2023-09-28 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with plaque psoriasis of the scalp

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
JP5350793B2 (ja) * 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション 改変抗ｉｌ−２３抗体
BRPI0620946B8 (pt) 2005-12-29 2021-05-25 Centocor Inc anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
EP2059534B1 (en) 2007-02-23 2012-04-25 Schering Corporation Engineered anti-il-23p19 antibodies
GEP201706733B (en) * 2010-11-04 2017-09-25 Boehringer Ingelheim Int Anti-il-23 antibodies
EP3326649B1 (en) * 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
CA2906382A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
US20160222102A1 (en) * 2015-02-04 2016-08-04 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
JP7090014B2 (ja) * 2018-11-07 2022-06-23 株式会社ミツバ ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法

Also Published As

Publication number Publication date
IL307578A (en) 2023-12-01
BR112017014684A2 (pt) 2018-01-09
WO2016126638A1 (en) 2016-08-11
EA201791734A1 (ru) 2018-01-31
JP7042298B2 (ja) 2022-03-25
SG11201705728RA (en) 2017-08-30
KR20170120616A (ko) 2017-10-31
IL253118A0 (en) 2017-08-31
JP2022081644A (ja) 2022-05-31
SG10202103879YA (en) 2021-05-28
EP3253794A1 (en) 2017-12-13
MX2022006573A (es) 2022-07-11
JP7042297B2 (ja) 2022-03-25
AU2021286378A1 (en) 2022-01-20
CA2972995A1 (en) 2016-08-11
CN107206081A (zh) 2017-09-26
AU2016215535B2 (en) 2021-09-16
CN113559258A (zh) 2021-10-29
JP2020125338A (ja) 2020-08-20
JP7044824B2 (ja) 2022-03-30
US20160222102A1 (en) 2016-08-04
JP2020125340A (ja) 2020-08-20
JP2018505882A (ja) 2018-03-01
MX2022006575A (es) 2022-07-11
AU2016215535A1 (en) 2017-07-13
JP2020125339A (ja) 2020-08-20
MX2017010037A (es) 2018-05-15
PH12017501378A1 (en) 2018-01-08
JP6758304B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
GT201700188A (es) Anticuerpos contra tau y sus usos
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
ECSP16075416A (es) Anticuerpos de il-21
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
CO2018004493A2 (es) Métodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f)
UY36286A (es) Tratamientos médicos basados en anamorelina
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis